35.95
price up icon4.04%   1.395
after-market アフターアワーズ: 35.95 -0.005 -0.01%
loading
前日終値:
$34.56
開ける:
$34.87
24時間の取引高:
2.65M
Relative Volume:
1.58
時価総額:
$4.33B
収益:
$10.12M
当期純損益:
$-280.49M
株価収益率:
-12.44
EPS:
-2.89
ネットキャッシュフロー:
$-188.51M
1週間 パフォーマンス:
+7.23%
1か月 パフォーマンス:
+23.85%
6か月 パフォーマンス:
+12.64%
1年 パフォーマンス:
-22.56%
1日の値動き範囲:
Value
$34.25
$36.03
1週間の範囲:
Value
$32.72
$37.59
52週間の値動き範囲:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
名前
Avidity Biosciences Inc
Name
セクター
Healthcare (1159)
Name
電話
858-401-7900
Name
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
391
Name
Twitter
Name
次回の収益日
2024-12-07
Name
最新のSEC提出書
Name
RNA's Discussions on Twitter

RNA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
35.95 4.37B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.54B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-10 再開されました Goldman Buy
2025-06-24 開始されました Bernstein Outperform
2025-06-17 開始されました Wolfe Research Outperform
2025-06-11 開始されました Raymond James Strong Buy
2025-03-13 開始されました Citigroup Buy
2025-03-12 開始されました BMO Capital Markets Outperform
2025-03-07 開始されました Scotiabank Sector Outperform
2024-12-20 開始されました H.C. Wainwright Buy
2024-11-26 開始されました RBC Capital Mkts Outperform
2024-09-24 開始されました Goldman Buy
2024-08-28 開始されました Barclays Overweight
2024-05-03 開始されました BofA Securities Buy
2024-03-14 開始されました Cantor Fitzgerald Overweight
2023-05-22 アップグレード Evercore ISI In-line → Outperform
2023-03-31 ダウングレード Evercore ISI Outperform → In-line
2022-07-20 開始されました Chardan Capital Markets Buy
2022-07-12 開始されました Raymond James Strong Buy
2021-09-07 開始されました Evercore ISI Outperform
2021-06-17 開始されました Needham Buy
2021-04-26 再開されました Credit Suisse Outperform
2020-07-07 開始されました Cowen Outperform
2020-07-07 開始されました Credit Suisse Outperform
2020-07-07 開始されました SVB Leerink Outperform
2020-07-07 開始されました Wells Fargo Overweight
すべてを表示

Avidity Biosciences Inc (RNA) 最新ニュース

pulisher
Jul 28, 2025

Trendline Breach Raises Concern for Avidity Biosciences Inc. InvestorsStable Entry High Return Opportunities in Focus - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences and the Potential for First-in-Class DM1 Therapy - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity completes enrollment for phase 3 trial of DM1 treatment By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Avidity Biosciences Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Avidity Biosciences Inc.Capitalize on fast-growing stocks today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Avidity Biosciences Inc. stock compared to the marketMaximize your returns with portfolio optimization - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Avidity Biosciences Inc. stock in 2025Get alerts on the hottest market movers - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Avidity Biosciences Inc. generate profit in a changing economyMassive stock growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy Avidity Biosciences Inc. stockExpert guidance for superior capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Avidity Biosciences Inc. stock attracting strong analyst attentionMaximize gains with timely market signals - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Avidity Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Avidity Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsDiscover stocks with superior performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Avidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Avidity’s Stock Surge: Time to Act? - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Avidity Biosciences Inc. stock priceFree Wealth Planning Blueprint - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 22, 2025

Avidity Biosciences Inc (RNA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
大文字化:     |  ボリューム (24 時間):